Zealand Pharma A/S (NASDAQ:ZEAL) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $12.48 and last traded at $12.65, with a volume of 2200 shares. The stock had previously closed at $12.75.

A number of brokerages recently issued reports on ZEAL. Morgan Stanley began coverage on Zealand Pharma A/S in a research note on Tuesday, September 5th. They set an “overweight” rating and a $28.00 price target for the company. Guggenheim began coverage on Zealand Pharma A/S in a research note on Tuesday, September 5th. They set a “buy” rating and a $28.00 price target for the company. Needham & Company LLC reissued a “buy” rating and set a $26.00 price target on shares of Zealand Pharma A/S in a research note on Monday, October 16th. Goldman Sachs Group began coverage on Zealand Pharma A/S in a research note on Wednesday, September 27th. They set a “buy” rating for the company. Finally, Zacks Investment Research raised Zealand Pharma A/S from a “hold” rating to a “buy” rating and set a $17.00 target price for the company in a research report on Wednesday, November 15th. Five equities research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average price target of $24.75.

Several large investors have recently made changes to their positions in the company. Jane Street Group LLC purchased a new position in Zealand Pharma A/S during the 3rd quarter worth $386,000. Royce & Associates LP acquired a new stake in Zealand Pharma A/S during the 3rd quarter worth about $1,152,000. Finally, Susquehanna International Group LLP acquired a new stake in Zealand Pharma A/S during the 3rd quarter worth about $3,185,000. Institutional investors and hedge funds own 13.33% of the company’s stock.

WARNING: “Zealand Pharma A/S (ZEAL) Reaches New 52-Week Low at $12.48” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.watchlistnews.com/zealand-pharma-as-zeal-reaches-new-52-week-low-at-12-48/1774944.html.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes.

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.